difference in neutropenia due to administration schedule of tas-102

Clicks: 115
ID: 235642
2017
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
TAS-102 significantly improves overall survival in patients with metastatic colorectal cancer. The most common adverse event of TAS-102 is bone marrow suppression, which leads to neutropenia. The incidence of neutropenia is high, and there is no known effective prevention method. Furthermore, the administration method of TAS-102 is complicated. We reported that neutropenia could be avoided by changing to a simple administration method of TAS-102.
Reference Key
yoshida2017casedifference Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Yoichiro Yoshida;Naoya Aisu;Ai Mogi;Akira Komono;Ryohei Sakamoto;Daibo Kojima;Toshiyuki Mera;Suguru Hasegawa
Journal multi-span large bridges - proceedings of the international conference on multi-span large bridges, 2015
Year 2017
DOI
10.1159/000460242
URL
http://www.karger.com/Article/FullText/460242
Keywords
Chemotherapy colorectal cancer Oncology including cancer and carcinogens tumors neutropenianeoplasms

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.